The potential for significant myelotoxicity with cytotoxic therapy, as well as the risk of hemorrhage and hemostatic derangements with anti-VEGF therapies, in this aggressive malignancy with few effective therapies, brings into sharp relief the significant therapeutic implications of any disease-associated coagulopathy. Here, VEGFA is linked to blood coagulation disease.